News Center
Follow the latest, from research findings, product launches of Tikva Allocell to industry trends and thought-provoking articles in the exciting field of CAR-T cells therapy. Stay informed, stay inspired, and stay connected right here at our News Center.
Stay tuned to our news
Press Releases
Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors
SINGAPORE and UNITED STATES — 22 JULY 2026 — Tikva Allocell today announced the successful closing of an $8 million Series A financing round, led by
Read More →
Tikva attending MedInvest Biotech & Pharma Investor Conference in September
Tikva Allocell will be attending MedInvest Biotech & Pharma Investor Conference from September 18 to 19.
Read More →
Tikva published paper on Novel OX40 and 4-1BB Derived Spacers Enhance CD30 CAR Activity and Safety in CD30 Positive Lymphoma Models
SINGAPORE – 8 Jul 2024 – Tikva Allocell Scientists published scientific article in Cell Molecular Therapy on Novel OX40 and 4-1BB Derived Spacers Enhance CD30
Read More →
Tikva published paper on enhancing allogeneic T-cell persistence and efficacy with overexpression of an Engineered SERPINB9
Research Article - Overexpression of an Engineered SerpinB9 Enhances Allogeneic T-Cell Persistence and Efficacy
Read More →
Tikva published paper on promising off-the-shelf CAR T cell therapy targeting B7-H3 positive solid tumors
SINGAPORE – 28 May 2024 – Tikva Allocell scientists publish scientific article in Cancer Research Communications on a promising off-the-shelf CAR T cell therapy targeting B7-H3
Read More →
Tikva Allocell joins the Johnson & Johnson Innovation – JLABS community
Tikva Allocell joins the Johnson & Johnson Innovation – JLABS community
Read More →
meet us here
Events
Tikva’s Head of Research, Dr. Lionel Low Keynote Presentation at 3rd Cell and Gene Therapy R&D Congress Asia
Dr. Lionel Low, Head of Research at Tikva Allocell, delivered a compelling keynote at the 3rd Cell and Gene Therapy R&D Congress Asia by Global
Read More →
CEO and Founder, Dr. Ivan Horak, to speak at the Clinical Trial Festival Asia 2025
Tikva Allocell announces that CEO and Founder, Ivan Horak, will speak at the 3rd Clinical Trial Festival Asia 2025 in Singapore, organized by IMAPAC.
Read More →
Tikva Allocell presented poster at the 16th FCS conference
Tikva Allocell presented poster at the 16th Frontiers in Cancer Science conference, held on 13-15 November 2023 at Matrix at Biopolis, Singapore.
Read More →
Dr Ivan Horak, CEO & Founder of Tikva Allocell received the Lifetime Achievement Award at APCGTEA 2024
Dr. Ivan D. Horak, CEO and Founder of Tikva Allocell (Tikva), received the Lifetime Achievement Award at APCGTEA 2024 in recognition for his contributions and leadership in the
Read More →
Tikva Allocell is One Year Old!
Tikva Allocell (Tikva), founded July 2023, celebrated our first year.
Read More →
Tikva Allocell Among Top 6 Finalists for the Amgen x NSG BioLabs Golden Ticket Awards 2024
Tikva Allocell was one of the top 6 finalist companies of the Amgen x NSG BioLabs Golden Ticket Award.
Read More →